Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
39 hedge funds and large institutions have $63.4M invested in Genocea Biosciences, Inc. in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.
269% more call options, than puts
Call options by funds: $992K | Put options by funds: $269K
103% more capital invested
Capital invested by funds: $31.1M → $63.4M (+$32.2M)
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
11% more funds holding
Funds holding: 35 → 39 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$13.3M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$8.27M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.23M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.61M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$2.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.21M |
| 2 |
Squarepoint
New York
|
-$280K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$276K |
| 4 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
-$264K |
| 5 |
FIA
FNY Investment Advisers
New York
|
-$262K |
GNCA Hedge Fund Activity: Q3 2020 in Review
39 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2020, worth a combined $63.4M — up 103% from $31.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GNCA positions and 8 closed out — a net gain of 4 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $13.3M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.21M sold.
- 39 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2020, up from 35 in Q2 2020.
- Funds reported $63.4M of Genocea Biosciences, Inc. stock for Q3 2020, up 103% quarter-over-quarter.
- 12 funds opened new Genocea Biosciences, Inc. positions in Q3 2020 and 8 closed out, a net change of +4 holders.
- The largest Genocea Biosciences, Inc. buyer in Q3 2020 was Avoro Capital Advisors, an estimated $13.3M added.
- The largest Genocea Biosciences, Inc. seller in Q3 2020 was DAFNA Capital Management, an estimated $1.21M sold.
Based on aggregated 13F filings for Q3 2020.